uptodate allopurinol | Pharmacologic urate-lowering therapy and treatm

Keyword	CPC	PCC	Volume	Score	Length of keyword
uptodate allopurinol	0.98	0.3	9351	64	20
uptodate	0.76	0.7	3459	57	8
allopurinol	0.18	0.9	1848	96	11

Keyword	CPC	PCC	Volume	Score
uptodate allopurinol	0.99	0.9	2100	29
uptodate allopurinol gout	1.04	0.3	8512	21
allopurinol dosing uptodate	0.54	0.8	9282	38
allopurinol renal dosing uptodate	1.39	0.8	5504	81
allopurinol side effects uptodate	0.55	0.2	8697	59
allopurinol medication uptodate clearance	0.06	0.5	9921	49
allopurinol uptodate clearance	1.56	0.4	2267	58
allopurinol dosage uptodate	1.64	0.5	749	20
allopurinol dose uptodate	0.59	0.3	9347	81

Search Results related to uptodate allopurinol on Search Engine

Pharmacologic urate-lowering therapy and treatment of tophi ... - UpToDate
uptodate.com

https://www.uptodate.com/contents/pharmacologic-urate-lowering-therapy-and-treatment-of-tophi-in-patients-with-gout

WebJan 16, 2018 · - Allopurinol. Dosing; Adverse effects; Drug interactions; Mechanism of action - Febuxostat. Dosing, drug interactions, and efficacy; Adverse effects; Uricosuric drugs - Indications - Combination therapy - Agents and dosing - Side effects and interactions - Other drugs; Uricase - Pegloticase - Rasburicase; MANAGEMENT OF GOUT IN …

DA: 58 PA: 35 MOZ Rank: 57

Treatment of gout flares - UpToDate
uptodate.com

https://www.uptodate.com/contents/treatment-of-gout-flares

WebNov 30, 2023 · These medications may include allopurinol, febuxostat, probenecid, benzbromarone, or pegloticase. There is no benefit to temporary discontinuation of these medications. Moreover, subsequent reintroduction of urate-lowering therapies may precipitate another flare.

DA: 63 PA: 37 MOZ Rank: 90

General drug information - UpToDate
uptodate.com

https://www.uptodate.com/contents/table-of-contents/drug-information/general-drug-information

WebAllopurinol: Drug information; All-trans retinoic acid (systemic tretinoin): Drug information; Almotriptan: Drug information; Alogliptin and metformin: Drug information; Alogliptin and pioglitazone: Drug information; Alogliptin: Drug information; Alosetron: Drug information; Alpelisib: Drug information; Alpha-1 proteinase inhibitor: Drug ...

DA: 30 PA: 80 MOZ Rank: 16

Patient education: Gout (Beyond the Basics) - UpToDate
uptodate.com

https://www.uptodate.com/contents/gout-beyond-the-basics

WebJan 18, 2024 · Allopurinol and febuxostat work by preventing the formation of urate. Allopurinol is the most common urate-lowering therapy. Rarely, it can cause side effects, including skin reactions (rash), lowered white blood cell …

DA: 20 PA: 16 MOZ Rank: 29

Asymptomatic hyperuricemia - UpToDate
uptodate.com

https://www.uptodate.com/contents/asymptomatic-hyperuricemia

WebApr 11, 2023 · Asymptomatic hyperuricemia is a term traditionally applied to settings in which the serum urate concentration is elevated but in which neither symptoms nor signs of monosodium urate (MSU) crystal deposition disease, such as gout, or uric acid renal disease, have occurred.

DA: 34 PA: 29 MOZ Rank: 18

Management of Gout: Update from the American College of …
aafp.org

https://www.aafp.org/pubs/afp/issues/2021/0800/p209.html

WebConsider starting allopurinol at 100 mg or less daily and febuxostat at 40 mg or less daily. Dosing should be increased every two to five weeks to reduce serum urate levels to 6 mg per dL (0.36...

DA: 89 PA: 95 MOZ Rank: 49

UpToDate
uptodate.com

https://www.uptodate.com/contents/search?search=allopurinol&sp=0&searchType=PLAIN_TEXT&source=USER_INPUT&searchControl=TOP_PULLDOWN&searchOffset=

Web{{configCtrl2.info.metaDescription}}

DA: 83 PA: 34 MOZ Rank: 32

Allopurinol - StatPearls - NCBI Bookshelf
nih.gov

https://www.ncbi.nlm.nih.gov/books/NBK499942/

WebJun 26, 2023 · Allopurinol, a xanthine oxidase inhibitor, is a urate-lowering medication. Allopurinol is FDA approved for the following indications: Gout. Prevention of tumor lysis syndrome. Prevention of recurrent calcium nephrolithiasis in patients with hyperuricosuria.

DA: 32 PA: 90 MOZ Rank: 14

Evidence reviews for timing of urate-lowering therapy in relation …
nih.gov

https://www.ncbi.nlm.nih.gov/books/NBK583523/

WebThe evidence showed a clinical harm for allopurinol when compared to placebo for joint inflammation and joint tenderness at medium-term (two to six weeks). The evidence showed no clinical difference for frequency of flares outcome at medium-term (two to six weeks).

DA: 4 PA: 57 MOZ Rank: 45

UpToDate
uptodate.com

https://us.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-gout/abstract/34

WebIf allopurinol toxicity occurs, options include other xanthine oxidase inhibitors, allopurinol desensitisation, or a uricosuric. The uricosuric benzbromarone is more effective than allopurinol (ES = 1.50 (0.76 to 2.24)) and can be used in patients with mild to moderate renal insufficiency but may be hepatotoxic.

DA: 62 PA: 70 MOZ Rank: 39